Goldman Sachs refreshes conviction lists on both sides of the Atlantic
Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction id…
Yahoo Finance
Updated Sep 1, 2026
Upgrade to a paid plan to see AI rating history on the chart.
Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction id…
How Vertex Pharmaceuticals Stock Has Been Trading Recently Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52…
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more t…
BOSTON, September 01, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharma…
OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appoint…
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant chal…
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNcE9VaEotZFVTcFB0dGpHVGVXeGs5MlhCeFJSZlcxSVBGLXhINGZSeHJrXzE0TFo3LWMxeTlMZWdYWnhCNVoxWTdSTTY5c1ZUd…
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Not investment advice. Past performance does not guarantee future results. Full disclaimer